InVivo Therapeutics Holdings Performance
| NVIVDelisted Stock | USD 1.38 0.07 5.34% |
The company retains a Market Volatility (i.e., Beta) of 0.52, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, InVivo Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding InVivo Therapeutics is expected to be smaller as well. InVivo Therapeutics right now retains a risk of 0.0%. Please check out InVivo Therapeutics sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if InVivo Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days InVivo Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable forward indicators, InVivo Therapeutics is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 10.7 M |
InVivo |
InVivo Therapeutics Relative Risk vs. Return Landscape
If you would invest 138.00 in InVivo Therapeutics Holdings on August 29, 2024 and sell it today you would earn a total of 0.00 from holding InVivo Therapeutics Holdings or generate 0.0% return on investment over 90 days. InVivo Therapeutics Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than InVivo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
InVivo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InVivo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InVivo Therapeutics Holdings, and traders can use it to determine the average amount a InVivo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NVIV |
Based on monthly moving average InVivo Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InVivo Therapeutics by adding InVivo Therapeutics to a well-diversified portfolio.
InVivo Therapeutics Fundamentals Growth
InVivo Stock prices reflect investors' perceptions of the future prospects and financial health of InVivo Therapeutics, and InVivo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InVivo Stock performance.
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) | |||
| Cash And Equivalents | 13.03 M | |||
| Cash Per Share | 9.36 X | |||
| Total Debt | 949 K | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Earnings Per Share | (3.28) X | |||
| Total Asset | 18.82 M | |||
| Retained Earnings | (248.62 M) | |||
| Current Asset | 20.74 M | |||
| Current Liabilities | 3.31 M | |||
About InVivo Therapeutics Performance
Evaluating InVivo Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if InVivo Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if InVivo Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Things to note about InVivo Therapeutics performance evaluation
Checking the ongoing alerts about InVivo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InVivo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InVivo Therapeutics is not yet fully synchronised with the market data | |
| InVivo Therapeutics may become a speculative penny stock | |
| InVivo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| InVivo Therapeutics Holdings currently holds about 13.03 M in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing InVivo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InVivo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining InVivo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InVivo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of InVivo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InVivo Therapeutics' stock. These opinions can provide insight into InVivo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |